Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 2/20 | 1.00 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.70 |
| ▸ | AURKA | O14965 | 7/20 | 0.59 |
| ▸ | GSK3B | P49841 | 5/20 | 0.59 |
| ▸ | GSK3A | P49840 | 4/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CDC7 | O00311 | 2/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3808883 | 0.99 | PLK1 (0.98) | PLK1PTK2BMEN1MAPTKMT2A | |
| SCHEMBL4025594 | 0.91 | PLK1 (0.84) | PLK1PTK2BMEN1MAPTKMT2A | |
| SCHEMBL23119030 | 0.91 | PLK1 (0.83) | PLK1PTK2BMEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL3810870 | 0.90 | PLK1 (0.82) | PLK1PTK2BMEN1MAPTKMT2A | |
| SCHEMBL13866466 | 0.90 | PLK1 (0.81) | PLK1PTK2BMEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL3814491 | 0.89 | PLK1 (0.80) | PLK1PTK2BMEN1MAPTKMT2A | |
| SCHEMBL13866473 | 0.84 | PLK1 (0.72) | PLK1PTK2BMEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL6176520 | 0.84 | PLK1 (0.72) | PLK1PTK2BMEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL3814314 | 0.83 | PLK1 (0.71) | PLK1PTK2BMEN1MAPTKMT2A | |
| SCHEMBL13809932 | 0.83 | PLK1 (0.70) | PLK1PTK2BMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | claimed |
| EP-1597251-B1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-06-10 | — | — | EP | claimed |
| US-20260124210-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF ANTI-CANCER AGENT(S) AND IMMUNE CHECKPOINT INHIBITOR(S) | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2026-05-07 | — | — | US | disclosed |
| US-12582658-B2 | Therapeutic constructs for co-delivery of anti-cancer agent(s) and immune checkpoint inhibitor(s) | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| EP-4479042-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240382492-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF ANTI-CANCER AGENT(S) AND IMMUNE CHECKPOINT INHIBITOR(S) | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-11-21 | — | — | US | disclosed |
| US-12059500-B2 | Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240110230-A1 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| CN-110913903-B | Glycan interaction compounds and methods of use | 思进股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20240000962-A1 | Glycan-Interacting Compounds and Methods of Use | SEAGEN INC. (US) | 2024-01-04 | — | — | US | disclosed |
| EP-3996750-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | Oregon Health & Science University (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220127682-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-28 | — | — | US | disclosed |
| WO-2022055721-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20220071906-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-03-10 | — | — | US | disclosed |
| CN-114096280-A | Therapeutic constructs for co-delivery of mitotic kinase inhibitors and immune checkpoint inhibitors | 俄勒冈健康与科学大学 | 2022-02-25 | — | — | CN | disclosed |
| EP-1597251-B1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-06-10 | — | — | EP | disclosed |
| US-7514446-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070010668-A1 | Pyrimidine compounds | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-01-11 | — | — | US | disclosed |
| US-20070010668-A1 | Pyrimidine compounds | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010668-A1 | Pyrimidine compounds | TYMS, TYMP, DPYD | PLK1 341/4885PTK2B 2046/4885MEN1 2558/4885 |
| US-12582658-B2 | Therapeutic constructs for co-delivery of anti-cancer agent(s) and immune checkpoint inhibitor(s) | PLK1, BUB1, WEE1 | PLK1 1/4885PTK2B 617/4885MEN1 814/4885 |
| US-20220127682-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | PLK4, PLK2, BUB1B | PLK1 5/4885PTK2B 759/4885MEN1 1144/4885 |
| US-20260124210-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF ANTI-CANCER AGENT(S) AND IMMUNE CHECKPOINT INHIBITOR(S) | PLK1, BUB1, BUB1B | PLK1 1/4885PTK2B 670/4885MEN1 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.